MedTrace Logo

Vitamin D Therapy to Prevent Recurrent Preeclampsia in High-Risk Pregnancies

NCT07717931 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2026-07-21

No results posted yet for this study

Summary

The goal of this clinical trial is to determine whether vitamin D supplementation can reduce the recurrence of preeclampsia in pregnant women with a previous history of preeclampsia.

The main questions the study aims to answer are:

\- Does daily vitamin D supplementation reduce the recurrence of preeclampsia compared with a placebo?

Researchers will randomly assign 146 eligible pregnant women to receive either vitamin D supplements or a placebo. The two groups will be compared to determine whether vitamin D lowers the risk of recurrent preeclampsia.

Participants will:

* Be randomly assigned to receive either 4000 IU oral vitamin D once daily or a matching placebo.
* Take the assigned study medication daily until 36 weeks of gestation.
* Attend follow-up visits every 2 weeks for blood pressure measurement and clinical assessment.
* Have serum vitamin D levels measured every 4 weeks to monitor for vitamin D toxicity.
* Undergo urine testing for protein if blood pressure is elevated to assess for preeclampsia.

The results of this study will help determine whether vitamin D supplementation is an effective and safe strategy for preventing recurrent preeclampsia in women at high risk.

Conditions

Interventions

DRUG

Vitamin D (Cholecalciferol )

Vitamin D 4000 IU will be administered orally once daily from enrollment until 36 weeks of gestation. They will attend follow-up visits every 2 weeks for blood pressure monitoring and clinical assessment, with serum vitamin D levels measured every 4 weeks.

DRUG

Placebo

A matching placebo with the same taste, color, and consistency as vitamin D will be administered orally once daily from enrollment until 36 weeks of gestation for comparison with vitamin D supplementation.

Sponsors & Collaborators

  • CMH Multan Institute of Medical Sciences

    lead OTHER_GOV

Principal Investigators

  • Nidda Y Assistant Professor, FCPS · CMH Multan Institute of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07717931 on ClinicalTrials.gov